Results 71 to 80 of about 2,191 (109)

Efficacy of intralesional meglumine antimoniate in the treatment of canine tegumentary leishmaniasis: A Randomized controlled trial. [PDF]

PLoS Negl Trop Dis, 2023
Lago J, Fraga D, Guimarães LH, Lago T, Silva YJ, Lago E, Werneck GL, Bacellar O, Carvalho EM.   +8 more
europepmc   +1 more source

Disseminated cutaneous leishmaniasis caused by Leishmania braziliensis in Southern Brazil

Revista do Instituto de Medicina Tropical de São Paulo
The authors report a case of disseminated cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis, in a 55 years old patient with 1,119 lesions distributed throughout the body.
Norberto Assis Membrive, Flávio Jun Kazuma, Thaís Gomes Verzignassi Silveira, Jorge Juarez Vieira Teixeira, Kárin Rosi Reinhold-Castro, Ueslei Teodoro   +5 more
doaj   +1 more source

Intralesional Meglumine Antimoniate: Safe, Feasible and Effective Therapy for Cutaneous Leishmaniasis in Bolivia. [PDF]

Trop Med Infect Dis, 2022
Rojas Cabrera E, Verduguez-Orellana A, Tordoya-Titichoca IJ, Sejas C, Ledezma R, Álvarez I, Limachi-Choque J, Ortuño-Gutiérrez N, Córdova Rojas M, Guzman-Rivero M.   +9 more
europepmc   +1 more source

Is There Any Difference in the In Situ Immune Response in Active Localized Cutaneous Leishmaniasis That Respond Well or Poorly to Meglumine Antimoniate Treatment or Spontaneously Heal? [PDF]

Microorganisms, 2023
Leite-Silva J, Oliveira-Ribeiro C, Morgado FN, Pimentel MIF, Lyra MR, Fagundes A, Miranda LFC, Valete-Rosalino CM, Schubach AO, Conceição-Silva F.   +9 more
europepmc   +1 more source

Molecular-based detection of Leishmania tropica isolates among sensitive, resistant, and relapsed patients treated with Meglumine Antimoniate. [PDF]

J Parasit Dis, 2022
Vazin A, Heidaripour MS, Kalantari M, Hatam G.   +3 more
europepmc   +1 more source

Immuno-pharmacokinetics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis Caused by Leishmania (Viannia). [PDF]

Clin Infect Dis, 2021
Gómez MA, Navas A, Prieto MD, Giraldo-Parra L, Cossio A, Alexander N, Gore Saravia N.   +6 more
europepmc   +1 more source

AgNP-PVP-meglumine antimoniate nanocomposite reduces Leishmania amazonensis infection in macrophages. [PDF]

BMC Microbiol, 2021
Gélvez APC, Diniz Junior JAP, Brígida RTSS, Rodrigues APD.   +3 more
europepmc   +1 more source

Neutrophil Activation: Influence of Antimony Tolerant and Susceptible Clinical Strains of L. (V.) panamensis and Meglumine Antimoniate. [PDF]

Front Cell Infect Microbiol, 2021
Fernández OL, Ramírez LG, Díaz-Varela M, Tacchini-Cottier F, Saravia NG.   +4 more
europepmc   +1 more source

Preparation and Evaluation of Clinical Effects of Glucantime Gel Mask

مجله دانشکده پزشکی اصفهان, 2013
Background: Pentavalent antimony compounds are the main treatment for cutaneous leishmaniasis. Usually, this drug is injected into the lesion for acute treatment, which is very painful and results in low patient compliance.
Sayed Abolfazl Mostafavi, Mohammad Ali Shatalebi, Ahmad Movahedian Attar, Hossein Hejazi, Amin Mottaghinejad, Reza Fadaei, Javad Ramezanpour, Parastuo Zarrinzamir   +7 more
doaj  

Low doses of 3-phenyl-lawsone or meglumine antimoniate delivery by tattooing route are successful in reducing parasite load in cutaneous lesions of Leishmania (Viannia) braziliensis-infected hamsters. [PDF]

Front Cell Infect Microbiol, 2023
Meira RMV, Gomes SLDS, Schaeffer E, Da Silva T, Brito ACS, Siqueira LM, Inácio JD, Almeida-Amaral EE, Da-Cruz AM, Bezerra-Paiva M, Neves RH, Rodrigues LS, Dutra PML, Costa PRR, da Silva AJM, Da-Silva SAG.   +15 more
europepmc   +1 more source